Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...
Zacks.com on MSN4d
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma StudyShares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...
On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.
Investorideas.com ( a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, ...
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback